Ocuphire Pharma (OCUP) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

CEO pay ratio

CEO Salary

Median Employee Salary

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Carbon Climate Environment Environmental Extreme Weather Life Cycle Materials Nature Offset Package Packaging Pandemic Plastic Raw Materials Access African American Asian Benefits Black Charity Collective Bargaining Community Customer Death Demographic Demographics Disability Diversity Drug Pricing Employee Engagement Ethnicity Gender Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Incident Injuries Injury Labor Condition Latinx LGBTQ Privacy Product Safety Recall Recruit Recruitment Reimbursement Retention Safety Satisfaction Skills Social Society Stakeholder Supplier Supply Chain Training Union Volunteer Women Workers Workforce Anti-corruption Assessment Assurance Audit Bonus Bribery Chronic Classified Commitment Corporate Governance Department of Ethics Executive Compensation Expert Fined Fraud Goals Governance Hedging Incentive Independence Independent Innovation Innovative Investigation Lawsuit Lead Independent Director Leadership Litigation Long-term Majority Oversee Oversight Purpose R&D Reputation Reputational Research and Development Responsibility Responsible Special Meeting Strategy Sustainable Targets Tax Tenure Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

At the 2022 annual meeting of stockholders of the Company held on June 13, 2022 (the “Annual Meeting”), stockholders (i) elected seven directors to the Company’s Board to serve a one-year term until the 2023 annual meeting of stockholders and (ii) ratified the appointment of Ernst & Young, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.
A total of 11,578,018 shares of the Company’s common stock were present at the meeting in person or by proxy, which represents approximately 60.19% of the shares of common stock outstanding as of the record date for the Annual Meeting.
The results of the voting are shown below:
Proposal 1—Election of Directors

Nominee	Votes For		Votes Withheld		Broker Non- Votes
Mina Sooch		6,595,980		162,350		4,819,688
Cam Gallagher		6,555,075		193,256		4,829,687
Sean Ainsworth		6,441,608		316,723		4,819,687
James Manuso		6,595,074		163,457		4,819,487
Richard Rodgers		6,595,181		163,150		4,819,687
Susan Benton		6,596,181		162,150		4,819,687
Jay Pepose		6,594,974		163,357		4,819,687

Proposal 2—Ratification of Appointment of Independent Registered Public Accounting Firm

Votes For				Votes Against				Votes Abstain
	11,487,772				15,859				74,387